Publication: Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 in mice
Issued Date
2007-04-01
Resource Type
ISSN
15566811
Other identifier(s)
2-s2.0-34248386524
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical and Vaccine Immunology. Vol.14, No.4 (2007), 342-347
Suggested Citation
Pimmada Jeamwattanalert, Yuvadee Mahakunkijcharoen, Leera Kittigul, Pakpimol Mahannop, Sathit Pichyangkul, Chakrit Hirunpetcharat Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 in mice. Clinical and Vaccine Immunology. Vol.14, No.4 (2007), 342-347. doi:10.1128/CVI.00397-06 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/24217
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 in mice
Other Contributor(s)
Abstract
Merozoite surface protein 1 (MSP1) is the major protein on the surface of the plasmodial merozoite, and its carboxy terminus, the 19-kDa fragment (MSP119), is highly conserved and effective in induction of a protective immune response against malaria parasite infection in mice and monkeys. However, the duration of the immune response has not been elucidated. As such, we immunized BALB/c mice with a standard four-dose injection of recombinant Plasmodium yoelii MSP119 formulated with Montanide ISA51 and CpG oligodeoxynucleotide (ODN) and monitored the MSP119-specific antibody levels for up to 12 months. The antibody titers persisted constantly over the period of time without significant waning, in contrast to the antibody levels induced by immunization with Freund's adjuvant, where the antibody levels gradually declined to significantly lower levels 12 months after immunization. Investigation of immunoglobulin G (IgG) subclass longevity revealed that only the IgG1 antibody level (Th2 type-driven response) decreased significantly by 6 months, while the IgG2a antibody level (Th1 type-driven response) did not change over the 12 months after immunization, but the boosting effect was seen in the IgG1 antibody responses but not in the IgG2a antibody responses. After challenge infection, all immunized mice survived with negligibly patent parasitemia. These findings suggest that protective immune responses to MSP119 following immunization using oil-based Montanide ISA51 and CpG ODN as an adjuvant are very long-lasting and encourage clinical trials for malaria vaccine development. Copyright © 2007, American Society for Microbiology. All Rights Reserved.